{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:55:12Z","timestamp":1767135312461,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011579","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000}}],"reference-count":76,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011579.pub2","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T12:15:05Z","timestamp":1476792905000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias"],"prefix":"10.1002","volume":"2023","author":[{"given":"Wai Cheng","family":"Foong","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; RCSI & UCD Malaysia Campus (formerly Penang Medical College); George Town Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline J","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; RCSI & UCD Malaysia Campus (formerly Penang Medical College); George Town Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C Khai","family":"Loh","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Universiti Kebangsaan Malaysia Medical Centre; 56000 Cheras Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[{"name":"Haematology\/Oncology Division, Department of Paediatrics; Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD011579.pub2-BIB0001|cit1","first-page":"191","article-title":"Optimizing the dose of hydroxyurea in thalassemia intermedia (Conference abstract)","volume":"28","author":"Bohara","year":"2012","journal-title":"Indian Journal Hematology Blood Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/03630269.2013.845844","article-title":"Optimizing the dose of hydroxyurea therapy for patients with beta-thalassemia intermedia (Hb E-beta-thalassemia): a single center study from Eastern India","volume":"38","author":"Bohara","year":"2014","journal-title":"Hemoglobin"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011579.pub2-BIB0003|cit3","first-page":"S448","article-title":"The role of hydroxyurea and valproic acid in the management of severe HbE-\u00df thalassaemia (Conference abstract)","volume":"30","author":"Biswas","year":"2014","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"issue":"6","key":"10.1002\/14651858.CD011579.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.12182","article-title":"Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young beta-thalassemia intermedia patients","volume":"91","author":"Elalfy","year":"2013","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2009.01356.x","article-title":"Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia","volume":"84","author":"Karimi","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0006|cit6","first-page":"806","article-title":"[Curative effects of hydroxyurea on the patients with beta-thalassaemia Intermedia]","volume":"24","author":"Huang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue za Zhi [Journal of Experimental Hematology]"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0007|cit7","unstructured":"Haghpanah S Karimi M Comparison of the efficacy and safety of herbal product (Resveratrol) with Hydroxyurea (HU) in non- transfusion- dependent B-thalassemia-intermedia http:\/\/www.irct.ir\/searchresult.php?id=20051&number=2"},{"issue":"11","key":"10.1002\/14651858.CD011579.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1182\/blood.V97.11.3411","article-title":"Cardiac involvement in thalassemia intermedia: a multicenter study","volume":"97","author":"Aessopos","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-0609.2011.01620.x","article-title":"Comparative study of pulmonary circulation and myocardial function in patients with beta-thalassemia intermedia with and without hydroxyurea, a case-control study","volume":"87","author":"Amoozgar","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MPH.0b013e31821b0770","article-title":"Efficacy of hydroxyurea in providing transfusion independence in beta-thalassemia","volume":"33","author":"Ansari","year":"2011","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"15","key":"10.1002\/14651858.CD011579.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","article-title":"Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders","volume":"120","author":"Bauer","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD011579.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/00365518609083733","article-title":"The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein","volume":"46","author":"Baynes","year":"1986","journal-title":"Scandinavian journal of clinical and laboratory investigation"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2007.06654.x","article-title":"Modern treatment of thalassaemia intermedia","volume":"138","author":"Borgna-Pignatti","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD011579.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1537-2995.2007.01399.x","article-title":"Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia","volume":"47","author":"Bradai","year":"2007","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0015|cit15","first-page":"58","article-title":"Thalassemia intermedia","volume":"80","author":"Camaschella","year":"1995","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/adc.65.3.304","article-title":"Partial splenectomy in homozygous beta thalassaemia","volume":"65","author":"Montalembert","year":"1990","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1034\/j.1600-0609.2003.00037.x","article-title":"Long-term hydroxyurea therapy in beta-thalassaemia patients","volume":"70","author":"Paula","year":"2003","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0018|cit18","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD011579.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00277-005-1026-4","article-title":"Hydroxyurea in thalassemia intermedia--a promising therapy","volume":"84","author":"Dixit","year":"2005","journal-title":"Annals of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD011579.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00277-014-2154-5","article-title":"Response to hydroxycarbamide in pediatric beta-thalassemia intermedia: 8 years' follow-up in Egypt","volume":"93","author":"El-Beshlawy","year":"2014","journal-title":"Annals of Hematology"},{"issue":"8","key":"10.1002\/14651858.CD011579.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V87.3.887.bloodjournal873887","article-title":"Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia\/hemoglobin E disease","volume":"87","author":"Fucharoen","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0023|cit23","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool McMaster University, 2015 (developed by Evidence Prime, Inc.) 2015"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0024|cit24","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0025|cit25","unstructured":"Higgins JPT Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0026|cit26","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0027|cit27","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD011579.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R","article-title":"Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia","volume":"62","author":"Hoppe","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"1-2","key":"10.1002\/14651858.CD011579.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cca.2009.06.019","article-title":"Response to hydroxyurea in beta thalassemia major and intermedia: experience in Western India","volume":"407","author":"Italia","year":"2009","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jcp.2009.070391","article-title":"Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study","volume":"63","author":"Italia","year":"2010","journal-title":"Journal of Clinical Pathology"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202","article-title":"Hydroxyurea for sickle cell disease","author":"Jones","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011579.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/01.mph.0000174386.13109.28","article-title":"Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran","volume":"27","author":"Karimi","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/08880011003639952","article-title":"Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience","volume":"27","author":"Karimi","year":"2010","journal-title":"Pediatric Hematology and Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0034|cit34","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0035|cit35","first-page":"65","article-title":"Hemoglobinopathies: a longitudinal study over four decades","volume":"107","author":"Kohne","year":"2010","journal-title":"Deutsches Arzteblatt International"},{"issue":"31-2","key":"10.1002\/14651858.CD011579.pub2-BIB0036|cit36","first-page":"532","article-title":"Hemoglobinopathies: clinical manifestations, diagnosis, and treatment","volume":"108","author":"Kohne","year":"2011","journal-title":"Deutsches Arzteblatt International"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0037|cit37","first-page":"74","article-title":"Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients","volume":"25","author":"Kosaryan","year":"2009","journal-title":"Pakistan Journal of Medical Sciences Quarterly"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/03630269.2013.869229","article-title":"Report on patients with non transfusion-dependent beta-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013","volume":"38","author":"Kosaryan","year":"2014","journal-title":"Hemoglobin"},{"issue":"4","key":"10.1002\/14651858.CD011579.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/03630269.2014.927770","article-title":"The effect and side effect of hydroxyurea therapy on patients with beta-thalassemia: a systematic review to December 2012","volume":"38","author":"Kosaryan","year":"2014","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2141.2006.06002.x","article-title":"Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up","volume":"133","author":"Mancuso","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0041|cit41","unstructured":"Matta BN Abbas O Maakaron JE Koussa S Daderian RH Taher AT Leg ulcers in patients with beta-thalassaemia intermedia: a single centre's experience Journal of the European Academy of Dermatology and Venereology 10.1111\/jdv.12211 23848223"},{"issue":"10","key":"10.1002\/14651858.CD011579.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2007-05-093419","article-title":"The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans","volume":"110","author":"Menzel","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1751-553X.2007.00965.x","article-title":"Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review","volume":"30","author":"Meo","year":"2008","journal-title":"International Journal of Laboratory Hematology"},{"issue":"11","key":"10.1002\/14651858.CD011579.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","article-title":"Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia","volume":"96","author":"Musallam","year":"2011","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0268-960X(12)70006-1","article-title":"Iron overload in non-transfusion-dependent thalassemia: a clinical perspective","volume":"26 Suppl 1","author":"Musallam","year":"2012","journal-title":"Blood reviews"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood-2011-09-382408","article-title":"Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia","volume":"119","author":"Musallam","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD011579.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"a013482","DOI":"10.1101\/cshperspect.a013482","article-title":"Beta-thalassemia intermedia: a clinical perspective","volume":"2","author":"Musallam","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Musallam KM Cappellini MD Daar S Karimi M El-Beshlawy A and Taher AT Serum Ferritin Levels and Morbidity in \u03b2-Thalassemia Intermedia: A 10-Year Cohort Study 54th ASH Annual Meeting and Exposition 2012","DOI":"10.1182\/blood.V120.21.1021.1021"},{"issue":"12","key":"10.1002\/14651858.CD011579.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassaemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.10842","article-title":"Liver iron concentrations and urinary hepcidin in beta-thalassemia","volume":"92","author":"Origa","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e2012001","DOI":"10.4084\/mjhid.2012.001","article-title":"Modulating effect of the -158 gamma (C-->T) Xmn1 polymorphism in Indian sickle cell patients","volume":"4","author":"Pandey","year":"2012","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011579.pub2-BIB0052|cit52","first-page":"357","article-title":"Hemoglobin E-beta thalassemia: factors affecting phenotype","volume":"42","author":"Panigrahi","year":"2005","journal-title":"Indian Pediatrics"},{"issue":"8147","key":"10.1002\/14651858.CD011579.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(79)92175-5","article-title":"Iron absorption and loading in beta-thalassaemia intermedia","volume":"2","author":"Pippard","year":"1979","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2012.074492","article-title":"Hydroxyurea responsiveness in beta-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity","volume":"98","author":"Pourfarzad","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0055|cit55","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2141.2010.08397.x","article-title":"Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients","volume":"151","author":"Rigano","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"5909","key":"10.1002\/14651858.CD011579.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science (New York, N.Y.)"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0058|cit58","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD011579.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2141.2005.05768.x","article-title":"Fetal haemoglobin augmentation in E\/beta(0) thalassaemia: clinical and haematological outcome","volume":"131","author":"Singer","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1345.031","article-title":"Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment","volume":"1054","author":"Singer","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St Pierre","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD011579.pub2-BIB0062|cit62","first-page":"401","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0063|cit63","unstructured":"Sterne JAC Egger M Moher D on behalf of the Cochrane Bias Methods Group (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD011579.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD011579.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pbc.24178","article-title":"Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children","volume":"59","author":"Strouse","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcmd.2006.04.005","article-title":"Thalassemia intermedia: revisited","volume":"37","author":"Taher","year":"2006","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"5","key":"10.1002\/14651858.CD011579.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2141.2009.07848.x","article-title":"Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies","volume":"147","author":"Taher","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD011579.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","article-title":"Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study","volume":"115","author":"Taher","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0069|cit69","first-page":"1","volume-title":"Guidelines for The Management of Non-transfusion Dependent Thalassaemia (NTDT)","author":"Taher","year":"2013"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0070|cit70","first-page":"12","volume-title":"Guidelines for The Management of Non-transfusion Dependent Thalassaemia (NTDT)","author":"Taher","year":"2013"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0071|cit71","first-page":"27","volume-title":"Guidelines for The Management of Non-transfusion Dependent Thalassaemia (NTDT)","author":"Taher","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD011579.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood.V99.1.10","article-title":"Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy","volume":"99","author":"Ware","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD011579.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0074|cit74","doi-asserted-by":"crossref","DOI":"10.1002\/9780470696705","volume-title":"The Thalassaemia Syndrome","author":"Weatherall","year":"2001"},{"key":"10.1002\/14651858.CD011579.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0268-960X(12)70003-6","article-title":"The definition and epidemiology of non-transfusion-dependent thalassemia","volume":"26 Suppl 1","author":"Weatherall","year":"2012","journal-title":"Blood reviews"},{"issue":"6","key":"10.1002\/14651858.CD011579.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","journal-title":"Blood"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011579.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:02:26Z","timestamp":1724112146000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011579.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011579.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}